Total Payments
$30,395
2024 Payments
$18,693
Companies
13
Transactions
38
Medicare Patients
281
Medicare Billing
$80,608
Payment Breakdown by Category
Consulting$27,264 (89.7%)
Food & Beverage$1,859 (6.1%)
Travel$1,272 (4.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $27,264 | 13 | 89.7% |
| Food and Beverage | $1,859 | 21 | 6.1% |
| Travel and Lodging | $1,272 | 4 | 4.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $7,495 | 8 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $7,004 | 5 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $6,371 | 7 | $0 (2024) |
| Janssen Biotech, Inc. | $2,615 | 4 | $0 (2024) |
| EMD Serono, Inc. | $2,115 | 1 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $1,734 | 1 | $0 (2023) |
| Janssen Global Services, LLC | $1,310 | 2 | $0 (2024) |
| Daiichi Sankyo Inc. | $1,253 | 4 | $0 (2024) |
| Mirati Therapeutics, Inc. | $163.72 | 2 | $0 (2023) |
| Novocure Inc. | $158.35 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,693 | 18 | Regeneron Pharmaceuticals, Inc. ($5,950) |
| 2023 | $7,189 | 15 | Genentech USA, Inc. ($3,070) |
| 2022 | $4,514 | 5 | Genentech USA, Inc. ($4,353) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $2,240.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,115.00 | General |
| 12/04/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $193.13 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $158.03 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: Oncology | ||||||
| 07/17/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $485.00 | General |
| 06/21/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $158.35 | General |
| Category: Oncology | ||||||
| 06/03/2024 | Genentech USA, Inc. | Alecensa (Biological), Rozlytrek | Food and Beverage | In-kind items and services | $72.05 | General |
| Category: BioOncology | ||||||
| 06/02/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 06/02/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| Category: Oncology | ||||||
| 06/02/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $31.27 | General |
| Category: ONCOLOGY | ||||||
| 04/21/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $82.44 | General |
| 03/22/2024 | Janssen Global Services, LLC | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,150.00 | General |
| Category: Oncology | ||||||
| 03/21/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| 02/23/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $3,570.00 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $2,380.00 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $51.86 | General |
| Category: ONCOLOGY | ||||||
| 02/22/2024 | Janssen Global Services, LLC | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $159.75 | General |
| Category: Oncology | ||||||
| 11/07/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $125.72 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $116.72 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $71.31 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $58.49 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $48.48 | General |
| Category: ONCOLOGY | ||||||
| 06/02/2023 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $127.43 | General |
| Category: BioOncology | ||||||
| 06/02/2023 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $16.50 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 172 | 462 | $182,256 | $54,017 |
| 2022 | 3 | 109 | 245 | $69,983 | $26,591 |
Total Patients
281
Total Services
707
Medicare Billing
$80,608
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 63 | 308 | $122,926 | $37,533 | 30.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 34 | 34 | $19,454 | $4,895 | 25.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 40 | $15,749 | $4,708 | 29.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 22 | 22 | $12,367 | $3,168 | 25.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 28 | $8,309 | $2,899 | 34.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 16 | 30 | $3,452 | $813.83 | 23.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 39 | 136 | $43,772 | $17,631 | 40.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 32 | 32 | $14,750 | $5,256 | 35.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 15 | $4,828 | $1,939 | 40.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 26 | 62 | $6,634 | $1,764 | 26.6% |
About Dr. Susan Scott, MD
Dr. Susan Scott, MD is a Hematology & Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/26/2015. The National Provider Identifier (NPI) number assigned to this provider is 1164816138.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Susan Scott, MD has received a total of $30,395 in payments from pharmaceutical and medical device companies, with $18,693 received in 2024. These payments were reported across 38 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($27,264).
As a Medicare-enrolled provider, Scott has provided services to 281 Medicare beneficiaries, totaling 707 services with total Medicare billing of $80,608. Data is available for 2 years (2022–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine, Medical Oncology
- Location Baltimore, MD
- Active Since 03/26/2015
- Last Updated 11/04/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1164816138
Products in Payments
- LIBTAYO (Biological) $8,105
- TAGRISSO (Drug) $5,138
- TECENTRIQ (Biological) $4,353
- RYBREVANT (Drug) $3,924
- Tecentriq (Biological) $3,070
- IMFINZI (Biological) $1,784
- KRAZATI (Drug) $163.72
- Optune Lua (NovoTTF-200T) (Device) $158.35
- Enhertu (Drug) $83.13
- Alecensa (Biological) $72.05
- TABRECTA (Drug) $50.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Baltimore
Miss. Ani Balmanoukian, M.d, M.D
Hematology & Oncology — Payments: $842,199
Hematology & Oncology $842,199
Dr. Benjamin Levy, Md, MD
Hematology & Oncology — Payments: $814,882
Hematology & Oncology $814,882
Dr. Patrick Forde, M.d, M.D
Hematology & Oncology — Payments: $253,665
Hematology & Oncology $253,665
Josephine Feliciano, M.d, M.D
Hematology & Oncology — Payments: $125,936
Hematology & Oncology $125,936
Djordje Atanackovic, M.d, M.D
Hematology & Oncology — Payments: $117,434
Hematology & Oncology $117,434
Huzefa Bahrain, D.o, D.O
Hematology & Oncology — Payments: $103,816
Hematology & Oncology $103,816